Humoral immune response after different SARS-CoV-2 vaccination regimens
상이한 SARS-COV-2 백신 접종 요법 후 체액 면역 반응
Research Article
[키워드] age
Alpha
anti-SARS-CoV-2
anti-SARS-CoV-2 IgG
antibody
Antibody Response
Antigen
AstraZeneca
avidity
AZD1222
B.1.1.7
B.1.1.7 variant
B.1.617.2
binding
BNT162b2
boost
booster vaccination
ChAdOx1
ChAdOx1 nCoV-19
comparable
Concentration
correlation
COVID-19
cVNT
delta variant
examined
first vaccination
followed by
Heterologous
homologous
humoral immune response
Humoral immunity
IgG
IgG antibodies
IgG antibody
immune response
immunoblot
Immunoglobulin
Immunoglobulin G
individual
investigation
leads
Maturity process
Moderna
mRNA
mRNA vaccine
neutralisation test
Neutralising Antibodies
Occurrence
Pfizer/BioNTech
Prevalence
RBD
Receptor binding domain
recipient
reduction in
regimen
Result
robust
S-protein
SARS-CoV-2
SARS-CoV-2 antigen
SARS-CoV-2 antigens
SARS-CoV-2 nucleoprotein
SARS-CoV-2 spike
SARS-CoV-2 vaccination
sera
Seroconversion
significantly higher
significantly lower
strength
subunit
supplementary material
sVNT
tested
the antibody response
the RBD
the SARS-CoV-2
the vaccine
titre
titres
trimeric
vaccination
Vaccination schemes
Vaccine
vaccine dose
vaccinee
variant
Virus neutralisation
Virus variants of concern
VoC
was done
was measured
was used
were measured
[DOI] 10.1186/s12916-021-02231-x PMC 바로가기 [Article Type] Research Article
[DOI] 10.1186/s12916-021-02231-x PMC 바로가기 [Article Type] Research Article